menu search

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zan...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zan...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zan...

October 10, 2021, 5:00 pm

Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene (NASDAQ: ...

October 7, 2021, 4:06 pm

Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene (NASDAQ: ...

October 7, 2021, 4:06 pm

Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene (NASDAQ: ...

October 7, 2021, 4:06 pm


Search within

Pages Search Results: